Cargando…
Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer
Two histone methyltransferases, enhancer of zeste homolog 2 (EZH2) and nuclear SET domain-containing 2 (NSD2), are aberrantly expressed in several types of human cancers. However, the regulatory relationship between EZH2 and NSD2 and their prognostic values in breast cancer (BC) have not been fully...
Autores principales: | Gao, Bo, Liu, Xiumin, Li, Zhengjin, Zhao, Lixian, Pan, Yun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7921704/ https://www.ncbi.nlm.nih.gov/pubmed/33665162 http://dx.doi.org/10.3389/fonc.2020.600514 |
Ejemplares similares
-
Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma
por: He, Chao, et al.
Publicado: (2019) -
Covalent inhibition of NSD1 histone methyltransferase
por: Huang, Huang, et al.
Publicado: (2020) -
Histone methyltransferase Nsd2 is required for follicular helper T cell differentiation
por: Long, Xuehui, et al.
Publicado: (2019) -
The role of histone lysine methyltransferase NSD3 in cancer
por: Han, Xu, et al.
Publicado: (2018) -
Identification of histone methyltransferase NSD2 as an important oncogenic gene in colorectal cancer
por: Zhao, Li-hao, et al.
Publicado: (2021)